Real-world outcomes of patients with advanced-stage hepatocellular carcinoma receiving combination therapy with atezolizumab and bevacizumab: A South Australian statewide experience

被引：0
|
作者：
Chan, A. [1 ,2 ]
Saluja, H. [1 ]
Nind, G. [3 ]
Singhal, N. [1 ]
Roy, A. [4 ]
Mcgregor, M. [2 ]
Chinnaratha, A. [2 ]
机构：
[1] Royal Adelaide Hosp, Adelaide, SA, Australia
[2] Lyell McEwin Hosp, Adelaide, SA, Australia
[3] Queen Elizabeth Hosp, Adelaide, SA, Australia
[4] Flinders Med Ctr, Adelaide, SA, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
118
引用
收藏
页码：56 / 57
页数：2
相关论文
共 50 条
  • [31] Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab
    Ha, Yeonjung
    Kim, Jee Hyun
    Cheon, Jaekyung
    Jeon, Gyeong Sik
    Kim, Chan
    Chon, Hong Jae
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (09) : 2421 - +
  • [32] Real-world experience of lenvatinib-based therapy in patients with advanced hepatocellular carcinoma
    Wang, Hung-Wei
    Lai, Hsueh-Chou
    Su, Wen-Pang
    Kao, Jung-Ta
    Hsu, Wei-Fan
    Chen, Hung-Yao
    Chang, Che-Wei
    Huang, Guan-Tarn
    Peng, Cheng-Yuan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (05)
  • [33] Hepatocellular Carcinoma Presenting with Pseudoprogression in a Patient Receiving Atezolizumab Plus Bevacizumab Combination Therapy
    Osuga, Takahiro
    Kubo, Tomohiro
    Miyanishi, Koji
    Ito, Ryo
    Sugawara, Taro
    Ohnuma, Hiroyuki
    Murase, Kazuyuki
    Takada, Kohichi
    INTERNAL MEDICINE, 2025,
  • [34] Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data
    Shimose, Shigeo
    Sugimoto, Rie
    Hiraoka, Atsushi
    Tanaka, Masatoshi
    Iwamoto, Hideki
    Tanaka, Yuki
    Tada, Fujimasa
    Ohama, Hideko
    Niizeki, Takashi
    Shirono, Tomotake
    Moriyama, Etsuko
    Noda, Yu
    Kamachi, Naoki
    Nakano, Masahito
    Kuromatsu, Ryoko
    Koga, Hironori
    Kawaguchi, Takumi
    HEPATOLOGY RESEARCH, 2023, 53 (02) : 116 - 126
  • [35] Atezolizumab and Bevacizumab for Treatment of Patients With Unresectable / Non-transplantable Advanced Hepatocellular Carcinoma: A Real-World Single Center Experience from North India
    Dhampalwar, Swapnil
    Choudhary, Narendra S.
    Saraf, Neeraj
    Bhangui, Prashant
    Soin, Arvinder S.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2024, 14 (01)
  • [36] Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
    Sae Yumita
    Sadahisa Ogasawara
    Miyuki Nakagawa
    Susumu Maruta
    Tomomi Okubo
    Norio Itokawa
    Yotaro Iino
    Masamichi Obu
    Yuki Haga
    Atsuyoshi Seki
    Tadayoshi Kogure
    Takamasa Ishino
    Keita Ogawa
    Kisako Fujiwara
    Terunao Iwanaga
    Naoto Fujita
    Takafumi Sakuma
    Ryuta Kojima
    Hiroaki Kanzaki
    Keisuke Koroki
    Masanori Inoue
    Kazufumi Kobayashi
    Soichiro Kiyono
    Masato Nakamura
    Naoya Kanogawa
    Tomoko Saito
    Takayuki Kondo
    Ryo Nakagawa
    Shingo Nakamoto
    Ryosuke Muroyama
    Tetsuhiro Chiba
    Ei Itobayashi
    Masanori Atsukawa
    Yoshihiro Koma
    Ryosaku Azemoto
    Kenji Ito
    Hideaki Mizumoto
    Jun Kato
    Naoya Kato
    BMC Gastroenterology, 23
  • [37] Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study"
    Nishida, Naoshi
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)
  • [38] Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
    Yumita, Sae
    Ogasawara, Sadahisa
    Nakagawa, Miyuki
    Maruta, Susumu
    Okubo, Tomomi
    Itokawa, Norio
    Iino, Yotaro
    Obu, Masamichi
    Haga, Yuki
    Seki, Atsuyoshi
    Kogure, Tadayoshi
    Ishino, Takamasa
    Ogawa, Keita
    Fujiwara, Kisako
    Iwanaga, Terunao
    Fujita, Naoto
    Sakuma, Takafumi
    Kojima, Ryuta
    Kanzaki, Hiroaki
    Koroki, Keisuke
    Inoue, Masanori
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Kanogawa, Naoya
    Saito, Tomoko
    Kondo, Takayuki
    Nakagawa, Ryo
    Nakamoto, Shingo
    Muroyama, Ryosuke
    Chiba, Tetsuhiro
    Itobayashi, Ei
    Atsukawa, Masanori
    Koma, Yoshihiro
    Azemoto, Ryosaku
    Ito, Kenji
    Mizumoto, Hideaki
    Kato, Jun
    Kato, Naoya
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [39] Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice
    Nakagawa, Miyuki
    Inoue, Masanori
    Ogasawara, Sadahisa
    Maruta, Susumu
    Okubo, Tomomi
    Itokawa, Norio
    Iino, Yotaro
    Obu, Masamichi
    Haga, Yuki
    Seki, Atsuyoshi
    Kikuchi, Yasuharu
    Kogure, Tadayoshi
    Yumita, Sae
    Ishino, Takamasa
    Ogawa, Keita
    Fujiwara, Kisako
    Iwanaga, Terunao
    Fujita, Naoto
    Sakuma, Takafumi
    Kojima, Ryuta
    Kanzaki, Hiroaki
    Koroki, Keisuke
    Taida, Takashi
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Kanogawa, Naoya
    Kondo, Takayuki
    Nakagawa, Ryo
    Nakamoto, Shingo
    Muroyama, Ryosuke
    Chiba, Tetsuhiro
    Itobayashi, Ei
    Atsukawa, Masanori
    Koma, Yoshihiro
    Azemoto, Ryosaku
    Ito, Kenji
    Mizumoto, Hideaki
    Shinozaki, Masami
    Kato, Jun
    Kato, Naoya
    CANCER, 2023, 129 (04) : 590 - 599
  • [40] Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
    Chon, Young Eun
    Kim, Dong Yun
    Kim, Mi Na
    Kim, Beom Kyung
    Kim, Seung Up
    Park, Yong
    Ahn, Sang Hoon
    Ha, Yeonjung
    Lee, Joo Ho
    Lee, Kwan Sik
    Kang, Beodeul
    Kim, Jung Sun
    Chon, Hong Jae
    Kim, Do Young
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (03)
12345